Bright Rex 4

4 · Menlo Therapeutics Inc. · Filed Mar 11, 2020

Form 4

Period: 2020-03-09

Director

Transactions

Award
Stock Options
2020-03-09+14,778→ 14,778 total
Exercise: $8.54From: 2020-03-09Exp: 2028-05-08→ Common Stock (14,778 underlying)
Award
Stock Options
2020-03-09+12,773→ 12,773 total
Exercise: $8.04Exp: 2027-07-12→ Common Stock (12,773 underlying)
Award
Stock Options
2020-03-09+29,271→ 29,271 total
Exercise: $4.50Exp: 2029-05-16→ Common Stock (29,271 underlying)
Award
Stock Options
2020-03-09+22,603→ 22,603 total
Exercise: $5.96Exp: 2030-02-27→ Common Stock (22,603 underlying)
Award
Stock Options
2020-03-09+15,994→ 15,994 total
Exercise: $9.93From: 2020-03-09Exp: 2024-12-29→ Common Stock (15,994 underlying)

Footnotes (4)

[F1]Received in or in connection with the merger of Foamix Pharmaceuticals Ltd. ("Foamix"), and Giants Merger Subsidiary Ltd., a direct, wholly owned subsidiary of Menlo Therapeutics Inc. ("Menlo"), in exchange for Foamix equity securities, as further described in the Form 4 filed by the Reporting Person on the date hereof in respect of the Reporting Person's interests in Foamix equity securities. The Reporting Person also received certain contingent stock rights which are subject to the terms and conditions of the contingent stock rights agreement, dated as of March 9, 2020, by and between American Stock Transfer & Trust Company, LLC and Menlo, or related contractual interests, either of which may entitle the Reporting Person to certain additional Menlo equity securities or the adjustment of certain Menlo equity securities, all as further described in that Current Report on Form 8-K filed by Menlo with the Securities and Exchange Commission on March 9, 2020.
[F2]The ordinary shares underlying this option vest over a period of four years (25% on July 13, 2017 and 6.25% every three months thereafter) ending July 13, 2021.
[F3]The ordinary shares underlying these options vest over a 12 month period, in equal, quarterly installments, ending May 16, 2020.
[F4]The ordinary shares underlying these options vest over a 12 month period, in equal, quarterly installments, ending February 27, 2021.

Documents

1 file